Merck & Co. announced this morning it will withdraw its arthritis drug Vioxx wordlwide.
Studies by the U.S. Food and Drug Administration indicate patients taking Vioxx have 50% higher risk of heart attack and sudden cardiac death than those taking Celebrex.
from a Merck & Co Press Release
Studies by the U.S. Food and Drug Administration indicate patients taking Vioxx have 50% higher risk of heart attack and sudden cardiac death than those taking Celebrex.
Merck is withdrawing the drug following data from a new three-year trial of Vioxx, designed to evaluate the effectiveness of the drug's standard 25 milligram dose in preventing recurrence of colorectal polyps. Such polyps often become cancerous.
In this study, there was an increased relative risk for confirmed cardiovascular events, such as heart attack and stroke, beginning after 18 months of treatment in the patients taking Vioxx compared to those taking placebo.
from a Merck & Co Press Release